Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney

• Published in: Journal of toxicology and environmental health Vol. 48; no. 6; p. 649
• Main Authors: Jeffery, E H, Abreo, K, Burgess, E, Cannata, J, Greger, J L
• Format: Journal Article
• Language: English
• Published: United States 30.08.1996
• Subjects: Aluminum - adverse effects; Animals; Bone and Bones - drug effects; Bone and Bones - physiopathology; Cell Membrane - drug effects; Cells - drug effects; GTP-Binding Proteins - drug effects; Hematopoietic System - drug effects; Hematopoietic System - physiopathology; Humans; Kidney - drug effects; Kidney - physiopathology; Minerals - metabolism; Oxidative Stress - drug effects; Research Design
• ISSN: 0098-4108
• DOI: 10.1080/009841096161122

Although the full mechanisms are not yet elucidated, research into the mechanism of toxicity of aluminum (Al) on bone formation and remodeling and on hematopoietic tissue is ongoing. In contrast little information exists on the interactive effects of systemic Al and the kidney. In bone, both clinically and experimentally, high doses of Al inhibit remodeling, slowing both osteoblast and osteoclast activities and producing osteomalacia and adynamic bone disease. In contrast, while very low levels of Al are mitogenic in bones of experimental animals, the effect of low levels of Al in humans is unknown. Aluminum has been shown to have its mitogenic action at the osteoblast, but whether the effect on resorption is viz osteoblast-directed changes in osteoclast activity has not yet been determined. Parathyroid hormone (PTH) levels are disrupted by Al in humans and animals. Whether altered PTH levels play a major or even a minor role in Al-dependent osteotoxicity requires clarification. In hematopoietic tissue, Al causes a microcytic anemia, not reversible by iron. Friend leukemia cells treated with Al have been reported to accumulate excess iron, without incorporating it into ferritin or heme. It is not yet known which steps in iron metabolism are disrupted by Al, if they involve a single mechanism of action, or even if this disruption in iron metabolism accounts for the anemia seen in Al toxicosis. In kidney, research is needed to evaluate Al nephrotoxicity; there are almost no studies in this area. Furthermore, research is needed to evaluate mechanisms of renal Al excretion, presently shown by one study to occur at the distal tubule. Such studies might well throw light on whether Al plays a role in aggravating renal insufficiency, or whether the role of the kidney in Al toxicosis is limited to the causative effect of renal compromise on Al accumulation. In summary, while a number of mechanisms have been proposed for the toxic action of Al, no single mechanism emerges to explain these diverse effects of systemic Al. Recommendations for future research are presented and summarized in Table 1.